The impact of Schistosoma haematobium infection and of praziquantel treatment on the growth of primary school children in Bertoua, Cameroon.
Our objective was to determine in a Cameroonian school population the effect of mild to moderate S. haematobium infection intensity on growth and development of children before and 6 months after praziquantel treatment. Previous studies have yielded contradictory results. Children from Bertoua schools were divided into four study groups: heavily infected (> 500 eggs 10 ml-1), moderately infected (1-499 eggs 10 ml-1) treated with praziquantel, a similar group treated with placebo, and an uninfected control group. Anthropometric measures--height for age per cent median (HAPM), and weight for age per cent median (WAPM)--were significantly higher among the uninfected children. Stepwise regression analysis showed that S. haematobium and Ascaris infections were the strongest predictors of the HAPM with hookworm and malaria infections playing a lesser role. Post treatment comparison of the praziquantel treatment group and the placebo group showed no significant differences for the anthropometric indicators except for mid-arm circumference. Longer observations of growth after treatment as well as monitoring of the rate of reinfection would be necessary to understand better the effect of S. haematobium on growth.
Befidi-Mengue
R N
RN
Institute of Medical Research and Study of Medicinal Plants (IMPM), Yaounde, Republic of Cameroon.
Ratard
R C
RC
D'Alessandro
A
A
Rice
J
J
Befidi-Mengue
R
R
Kouemeni
L E
LE
Cline
B L
BL
D000293:Adolescent; D000367:Age Factors; D000886:Anthropometry; D002163:Cameroon; D002648:Child; D006130:Growth Disorders / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D010270:Parasite Egg Count; D010272:Parasitic Diseases / Q000150:complications / Q000453:epidemiology; D011223:Praziquantel / Q000627:therapeutic use*; D015995:Prevalence; D011897:Random Allocation; D012044:Regression Analysis; D012553:Schistosomiasis haematobia / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology
D011223:Praziquantel